Tufts CSDD in the News
March 2011 | Tufts CSDD Internal News
Tufts CSDD's official response to the recent Light & Warburton commentary
Recently, you may have heard or read about a new article by Light and Warburton, entitled “Demythologizing the High Costs of Pharmaceutical Research,” in which the authors have attempted to critique and discredit CSDD"s 2003 study on the cost of new drug development by Joseph DiMasi et.al. Joe DiMasi"s peer-reviewed article has received worldwide recognition for its scholarship and scope, and its methodology has been critically examined and validated by the U.S. Office of Technology Assessment and others.
March 11, 2010 | Boston.com
Regulatory Workload Rises for Drug Firms
A growing volume of global drug development and commercialization activity has dramatically increased the workload for regulatory affairs professionals at pharmaceutical and biotech companies, the Tufts Center for the Study of Drug Development said in a new study.
March 5, 2010 | Bloomberg
Miracle Cancer Drug Extends Life With $48,720 Cost
The FDA has approved 25 targeted agents since 1998, the agency's Web site shows. With hundreds in development, 40 more could be on the market by 2015, according to a 2008 report by the Boston-based Tufts Center for the Study of Drug Development, which is affiliated with Tufts University.
February 21, 2010 | SouthCoast.com
Private Drug Tester Expands Stake in Big Pharma
The FDA preserves the integrity of testing in a landscape already pockmarked with potential conflicts of interest that include company-sponsored academic research and investigators testing drugs while owning shares in companies that own the drug, said Kenneth Getz, a senior fellow at Tufts University's Center for the Study of Drug Development.
February 8, 2010 | TherapeuticsDaily.com (sourced: BioWorld Today)
Myriad Ruling Could Have Broad Biotech Implications
The simple fact is that product launches are not keeping pace with patent expirations, said CSDD director Kenneth Kaitin. "Clinical development time for novel protein products, which now averages seven years, is unlikely to decrease due to disease complexity, growth of study protocols that lengthen studies and difficulty recruiting and retaining volunteers."
February 4, 2010 | Mass Device
Mayo Clinic Looks to Tap EMR Database to Craft Clinical Trials
"The simple fact is that product launches are not keeping pace with patent expirations," said CSDD director Kenneth Kaitin. "Clinical development time for novel protein products, which now averages seven years, is unlikely to decrease due to disease complexity, growth of study protocols that lengthen studies and difficulty recruiting and retaining volunteers."
January 19, 2010 | The Washington Times
Miller: Crushing Drug Research Momentum
Dr. Kenneth Kaitin, director of the Tufts Center for the Study of Drug Development, described the obstructionist culture at the FDA as having caused it to become viewed as "an agency that is supposed to keep unsafe drugs off the market, not to speed access to lifesaving drugs."
January 15, 2010 | Drug Discovery & Development
Pharma Outlook
"Industry is at a breaking point in terms of regulatory requirements imposed by the government and from being squeezed by productivity and economic downturns," said Christopher-Paul Milne, DVM, MPH, JD, associate director, Tufts University Center for the Study of Drug Development. "Companies are shutting down different parts of their operations with layoffs and downsizing," he told Drug Discovery & Development.
November 15, 2009 | New York Times
Seeking A Shorter Path to New Drugs
What’s smaller than a breadbox, can cost $800 million or more, and takes more than eight years to research and develop? A new medicine, according to data from the Tufts Center for the Study of Drug Development in Boston.
November 12, 2009
Chinese Hamster Ovary Cells Could Make More Drugs, Alnylam Says
By silencing certain genes in Chinese hamster ovary cells used to make protein medicines, Alnylam Pharmaceuticals Inc. may allow makers of biotechnology drugs to increase production.